FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

Narcolepsy type 1 is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, and other REM-related symptoms. Clinical trials supporting the approval demonstrated statistically significant improvements in both sleepiness scores and cataplexy frequency compared with placebo. According to the FDA, this is the first approved therapy to cover the full range of narcolepsy type 1 symptoms, offering a potential alternative to patients who currently use multiple medications. The approval is expected to be followed by post-marketing requirements to further characterize long-term safety.